Agenus Inc key statistics and ratios
In fiscal 2025, Agenus Inc had an operating margin of -17.7% and a current ratio of 0.41. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 97.3% | 98.8% | 89.2% | 98.0% | 99.5% | 99.1% | 99.5% |
| Operating margin | −830.1% | −647.5% | −692.6% | −42.2% | −820.3% | −620.9% | −325.2% | −476.1% | −242.1% | −336.6% | −46.7% | −133.0% | 8.7% | −183.0% | −102.1% | −116.4% | −17.7% | 27.3% |
| Net margin | −909.2% | −652.0% | −844.6% | −71.0% | −987.5% | −608.9% | −354.1% | −562.6% | −281.5% | −434.7% | −71.9% | −205.4% | −8.2% | −224.7% | −157.4% | −219.8% | −0.1% | 69.2% |
| Free-cash-flow margin | −732.9% | −443.2% | −591.6% | 5.7% | −668.1% | −588.4% | −204.6% | −409.7% | −227.0% | −366.2% | −15.6% | −161.7% | −8.0% | −233.0% | −149.8% | −153.6% | −67.6% | −74.2% |
| Return on equity | — | — | — | — | — | — | −187.5% | — | — | — | — | — | — | — | — | — | — | — |
| Return on assets | — | −70.9% | −91.8% | −46.3% | −94.1% | −77.7% | −55.5% | −63.6% | −81.7% | −116.4% | −73.9% | −97.9% | −7.1% | −50.1% | −67.6% | −84.2% | −0.0% | 46.0% |
| Asset turnover | — | 0.11 | 0.11 | 0.65 | 0.10 | 0.13 | 0.16 | 0.11 | 0.29 | 0.27 | 1.03 | 0.48 | 0.87 | 0.22 | 0.43 | 0.38 | 0.50 | 0.66 |
| Current ratio | — | 3.85 | 2.53 | 4.70 | 2.74 | 4.62 | 6.36 | 2.24 | 1.30 | 1.10 | 0.71 | 0.88 | 2.12 | 1.13 | 0.44 | 0.21 | 0.41 | 0.34 |
| Debt to equity | — | — | — | — | — | 27.2% | 161.9% | — | — | — | — | — | 40.1% | — | — | — | — | — |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | — | — | — | — | n/m | n/m | n/m | n/m | 0.6x |
| R&D as % of revenue | 506.9% | 383.3% | 400.0% | 66.2% | 427.1% | 320.3% | 283.9% | 420.7% | 270.8% | 338.7% | 112.2% | 161.8% | 60.4% | 190.5% | 150.1% | 150.3% | 69.5% | 43.5% |
| Capital spending as % of revenue | 7.3% | 3.9% | 2.0% | 0.6% | 26.7% | 40.4% | 14.5% | 55.5% | 7.3% | 9.8% | 3.1% | 3.9% | 11.4% | 54.1% | 6.4% | 0.6% | 0.0% | 0.0% |
| Free cash flow ÷ net income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −107.3% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 99.4% | 99.6% | 99.4% | 99.1% | 97.9% | 100.0% | 100.0% | 100.0% |
| Operating margin | −125.5% | −96.5% | −55.3% | −65.0% | −15.0% | 42.1% | 44.6% | 32.7% |
| Net margin | −264.6% | −171.1% | −105.2% | −109.0% | 211.2% | −31.1% | 116.1% | −1.7% |
| Free-cash-flow margin | −212.2% | −107.0% | −106.5% | −78.7% | −48.7% | −48.6% | −106.6% | −90.4% |
| Current ratio | 0.19 | 0.21 | 0.11 | 0.06 | 0.47 | 0.41 | 0.38 | 0.34 |
| R&D as % of revenue | 163.5% | 125.9% | 89.4% | 104.0% | 78.0% | 22.0% | 35.0% | 42.8% |
Financial health
- Short-term assets cover short-term liabilities $79m of assets due within a year against $232m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt $19m of cash against $60m of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$99m of operating cash flow against $60m of debt.
- Operating profit covers interest at least five times over Operating income of $36m against $59m of interest.
Moat
Weak moat
How hard Agenus's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -72.5% of total assets over 10 years.
- Pricing power 18 / 20
Gross margin has been a median 99.0%, moving by 3.7 percentage points (standard deviation) across 6 years.
- Durability 10 / 20
Operating margin has been a median -103.0%; its worst year was -410.3%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 10 years, at a median -121.2% of revenue.
- Discipline 10 / 20
The diluted share count fell 57.5% over five years; stock-based pay has been a median 17.8% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (39 before it).
Compare with peers
- Mesoblast LTD statistics
- Karyopharm Therapeutics Inc. statistics
- Arcus Biosciences, Inc. statistics
- ARS Pharmaceuticals, Inc. statistics
- Beam Therapeutics Inc. statistics
Head to head: AGEN vs MESOAGEN vs KPTIAGEN vs RCUSAGEN vs BEAM
More: Biotechnology stocks compared, Health Care sector, rankings of US companies